Company: BOLT
Filing Date: 2025-04-16
Form Type: PRE 14A
Source: 0000950170-25-054405
Chunk: 22

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-16
Form: PRE 14A
Chunk 22
---
 |     |  60 |     | Class II Director                                                      |
| Laura Berner (2)(3)*      |     |  50 |     | Class I Director                                                       |
| Kathleen LaPorte(1)*(2)   |     |  63 |     | Class III Director                                                     |
| Brian O’Callaghan(1)(2)*  |     |  55 |     | Class I Director                                                       |
| Nicole Onetto, M.D.(3)    |     |  72 |     | Class III Director                                                     |

(1) Member of the audit committee (2) Member of the compensation committee (3) Member of the nominating and corporate governance committee * Committee Chairperson Composition of our Board of Directors Our Board currently has three committees: (i) an audit committee, (ii) a compensation committee, and (iii) a nominating and corporate governance committee. The composition and responsibilities of each of the committees of our Board are described below. Members serve on these committees until their resignation or until otherwise determined by our Board. Our Board may establish other committees as it deems necessary or appropriate from time to time. Each committee operates under a charter that has been approved by our board and has the composition and responsibilities described below. The charters for each committee are available at the investor relations section of our website at www.boltbio.com. Audit Committee Our audit committee consists of Kathleen LaPorte, Brian O’Callaghan, and Jakob Dupont, M.D. Our Board reviews the Nasdaq listing standards definition of independence for audit committee members on an annual basis and has determined that each member of the audit committee satisfies the independence requirements under the Nasdaq listing standards and Rule 10A-3(b)(1) of the Exchange Act. The chairperson of our audit committee is Ms. LaPorte. Our Board has determined that Ms. LaPorte is an “audit committee financial expert” within the meaning of SEC regulations, based on a qualitative assessment of Ms. LaPorte’s level of knowledge and experience. Each member of our audit committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, our Board has examined each audit committee member’s scope of experience and the nature of their employment. The primary purpose of the audit committee is to discharge the responsibilities of our Board with respect to our corporate accounting and financial reporting processes, systems of internal control and financial statement audits, and to oversee our independent registered public accounting firm. Specific responsibilities of